AI Article Synopsis

  • Idic(X)(q13) is a rare chromosomal abnormality found in certain blood cancers, detailed through five new patient cases and literature review.
  • Three patients showed higher levels of bone marrow ringed sideroblasts, with most surviving after follow-up periods of 30-57 months.
  • The study suggests that this abnormality may significantly impact female-specific hematological malignancies, be linked to iron accumulation, and show varied prognoses.

Article Abstract

Idic(X)(q13) represents a rare but recurrent chromosomal abnormality in haematological malignancies. We present five new cases characterized by this particular aberration and review the literature on this subject. The patients were elderly females with a diagnosis of refractory anaemia (1/5), refractory anaemia with ringed sideroblasts (2/5), chronic myelomonocytic leukaemia (1/5), and Philadelphia chromosome-negative chronic myeloid leukaemia (1/5). Three out of the five patients demonstrated an increased proportion of bone marrow ringed sideroblasts. After a follow-up period of 30-57 months all patients but one are alive. Idic(X)(q13) always occurred as the sole chromosomal abnormality, either in one or in two copies. We confirmed the dicentric nature of the aberration by fluorescence in situ hybridization (FISH) on metaphases as well as interphase nuclei using an X-chromosome-specific alpha-satellite probe, and performed chromosome painting to visualize possible additional chromosomal changes involving the X chromosomes. Our findings and the data of 17 previously published cases indicate that idic(X)(q13): (1) may play a significant pathogenetic role in haematological malignancies affecting exclusively females and deriving predominantly from early progenitor cells; (2) is frequently associated with a pathological iron accumulation; (3) indicates a variable prognosis.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.1995.tb05405.xDOI Listing

Publication Analysis

Top Keywords

haematological malignancies
12
fluorescence situ
8
situ hybridization
8
hybridization fish
8
review literature
8
chromosomal abnormality
8
refractory anaemia
8
ringed sideroblasts
8
leukaemia 1/5
8
isodicentric xq13
4

Similar Publications

Autologous Stem-Cell Transplantation (ASTC) has proven efficacy in several hematological malignancies. The greatest antineoplastic effect achieved with intensified chemotherapy is associated with severe myelotoxicity. The infusion of autologous hematopoietic precursors and transfusion support during the period of aplasia reduces the time and depth of cytopenias, decreasing the risk of bleeding, anemia and life-threatening infections.

View Article and Find Full Text PDF

Objective: Gastrointestinal stromal tumor (GIST) is the most common type of mesenchymal tumor accounting for 2.2% of all malignant gastric tumors. Mesenchymal stem cells (MSCs) play crucial roles in gastric carcinogenesis.

View Article and Find Full Text PDF

10 years of BiTE immunotherapy: an overview with a focus on pancreatic cancer.

Front Oncol

December 2024

Research Department of Haematology, UCL Cancer Institute, University College London, London, United Kingdom.

Various therapeutic strategies have been developed to treat Pancreatic Cancer (PaCa). Unfortunately, most efforts have proved unfruitful, as the poor prognosis observed in this disease has only attained little improvement in the past 40 years. Recently, deeper understanding of the immune system and its interaction with malignant tumors have allowed significant advances in immunotherapy.

View Article and Find Full Text PDF

Hematopoietic stem cell microtransplantation: current situation and challenges.

Ther Adv Hematol

January 2025

Center of Hematology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) stands as a cornerstone in the treatment of hematological malignancies, recognized for its remarkable efficacy. However, the persistent challenge of graft-versus-host disease (GVHD) continues to represent a significant barrier, often being the leading cause of nonrelapse mortality after allo-HSCT. To address this limitation, hematopoietic stem cell microtransplantation (MST) has emerged as a novel therapeutic strategy that synergistically combines chemotherapy, allo-HSCT, and cellular immunotherapy.

View Article and Find Full Text PDF

SARS-COV-2 Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab in Haematological, Immunocompromised Patients in the Omicron Era.

Eur J Haematol

January 2025

Department of Haematology, Oncology, Immunology, Palliative Medicine, Infectious Diseases and Tropical Medicine, Muenchen Klinik Schwabing, Munich, Germany.

Background: Pre-exposure prophylaxis with tixagevimab-cilgavimab significantly reduced severe COVID-19 outcomes in high-risk individuals during the pre-Omicron era (PROVENT trial). However, efficacy in patients with haematological malignancies (HM) was underreported. The rapid emergence of Omicron strains in 2021 showed reduced neutralizing activity in preclinical data, but real-world data remains limited due to short follow-up.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!